Search

Your search keyword '"Minkov M"' showing total 9 results
Start Over Author "Minkov M" Language undetermined
9 results on '"Minkov M"'

1. Tabunka Sekai (Gensho-dai-san-han)

Author

Hofstede, G., Hofstede, G.J., and Minkov, M.

Subjects
Life Science, Toegepaste Informatiekunde, WASS, Information Technology
Published
2013

3. Kulturer og organisationer

Author

Hofstede, G., Hofstede, G.J., and Minkov, M.

Subjects
cultuur, cultureel gedrag, national consciousness, WASS, psychology, pluriforme samenleving, ethnic groups, nationaal bewustzijn, cross cultural studies, etnische groepen, nationalism, organisaties, cultural behaviour, nationalisme, organizations, communication, psychologie, international cooperation, Toegepaste Informatiekunde, plural society, communicatie, culture, intercultureel onderzoek, internationale samenwerking, culturele differentiatie, Information Technology, cultural differentiation
Abstract

Kultur er de grundfæstede og ofte ubevidste værdier vi er vokset op med. Det er de kulturelle forskelle der adskiller os fra de andre. Bogen afdækker de værdier, der kendetegner de forskellige kulturer - såvel de nationale og regionale som de organisatoriske. Forfatterne redegør for disse værdier via kulturelle dimensioner som forholdet mellem magt og lighed, forholdet mellem individ og gruppe, sociale roller for kvinder og mænd samt usikkerhedsundvigelse og krisehåndtering. Disse begreber og værdier gøres levende og vedkommende med en række eksempler fra dagligdagen rundt om i verden. Forfatterne viser desuden hvordan man håndterer det interkulturelle - dvs. slår bro over forskellene i de kulturelle værdinormer, f.eks. i internationale koncerner. Bogen henvender sig især til ledere, faglige specialister og forhandlere i såvel erhvervslivet som organisationer, hvor der arbejdes på tværs af de kulturelle skel. Men alle med interesse for interkulturelle forhold og ønske om en større kulturforståelse, kan få glæde af denne spændende bog. I denne ajourførte 3. udgave medvirker Michael Minkov som ny medforfatter. Dette har bl.a. betydet, at datagrundlaget er udvidet med en række østeuropæiske lande, således at resultater, eksempler og kulturmodeller er blevet endnu bedre og mere nuancerede.

Published
2010

6. Observations and Orbits of Comets

Author

Bernal, A., Codina, J. M., Nunez, J., Torras, N., Sunay Ibryamov, Bacci, P., Tesi, L., Fagioli, G., Mikuz, H., Kornos, L., Casali, M., Coffano, A., Marinello, W., Micheli, M., Pizzetti, G., Cernis, K., Selevicius, H., Haver, R., Jaeger, M., Prosperi, E., Vollmann, W., Foglia, S., Galli, G., Buzzi, L., Hasubick, W., Donati, S., Scotti, J. V., Seki, T., Rodriguez, D., Hodosan, G., Marschalko, G., Sarneczky, K., Gilmore, A. C., Kilmartin, P. M., Arnold, L., Kelemen, J., Baransky, A., Johnson, J. A., Boattini, A., Christensen, E. J., Gibbs, A. R., Grauer, A. D., Hill, R. E., Kowalski, R. A., Larson, S. M., Mcnaught, R. H., Shelly, F. C., Wetterer, A., Durig, D. T., Morris, T. A., Ikari, Y., Castellano, J., Vidal, J. R., Storey, D., Denzau, H., Vanssay, J. B., Klotz, A., Kugel, F., Nicolas, J., Fratev, F., Minkov, M., Linder, J., Beck, S., Martignoni, M., Audejean, M., Bryssinck, E., Soulier, J. F., Diepvens, A., Jorba, A., Zilch, T., Gerke, V., Plaksa, S., Aledo, J., Shurpakov, S., Dangl, G., Gaitan, J., Jahn, J., Hills, K., Takahashi, T., Herald, D., Drummond, J., Primak, N., Schultz, A., Goggia, T., Chambers, K., Oreshko, A., Paul, N., Sato, H., Williams, G. V., Marsden, C. L., Sherrod, P. C., Sherrod, L. P., Transient Factory, P., Waszczak, A., Lozano, J., Martin, J. L., Buczynski, D., Suzuki, M., Limon, F., Gonzalez, J., Abreu, D., Ruiz, P., Koschny, D., Busch, M., Schwab, E., Bill, H., Hormuth, F., Knoefel, A., Lehmann, G., Reszelewski, R., Schmalz, S., Thommes, T., Pena Ciriza, F., Garcia, F., Canales, O., Fletcher, J., Birtwhistle, P., Loudeche, A., Tsai, S. -H, Yen, Y. -C, Tsai, Y. -S, Noguchi, T., Novichonok, A., Prystavski, T., Lister, T., Maury, A., F Soulier, J., Carlos Soldan Alfaro, F., and Soldan A, F.

8. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE

Author

Maria Otth, Eva Brack, Pamela R Kearns, Olga Kozhaeva, Marko Ocokoljic, Reineke A Schoot, Gilles Vassal, Federica Achini, Adriana Balduzzi, Maja Beck Popovic, Auke Beishuizen, Luca Bergamaschi, Andrea Biondi, Franck Bourdeaut, Elena Braicu, Jesper Brok, Laurence Brugières, Amos Burke, Gabriele Calaminus, Michela Casanova, Marie-Louise Choucair, Morgane Cleirec, Selim Corbaciouglu, Maria Genoveva Correa Llano, Teresa De Rojas, Nerea Domínguez Pinilla, Caroline Elmaraghi, Andrea Ferrari, Alexander Fossa, Nathalie Gaspar, Nikolas Herold, Kyriaki Karapiperi, Maarja Karu, Mimi Kjærsgaar, Fabian Knörr, Christa Koenig, Izabela Kranjcec, Malgorzata Krawczyk, Kai Lehmberg, Thomas Lehrnbecher, Maaike Lunesink, Davide Massano, Nuša Matijasic, Hans Merks, Markus Metzler, Anthony Michalski, Milen Minkov, Bruce Morland, Naghmeh Niktoreh, Elena Oltenau, Daniel Orbach, Cormac Owens, Smaragda Papachristidou, Claudia Pasqualini, Maja Pavlovic, Paula Perez Albert, Fiona Poyer, Ivana Radulovic, Dirk Reinhardt, Joana Rebelo, Eva Roser, Ida Russo, Katrin Scheinemann, Christina Schindera, Martin Schrappe, Astrid Sehested, Jalid Sehouli, Filippo Spreafico, Sandra J Strauss, Janine Stutterheim, Karel Svojgr, Vasiliki Tzotzola, Roelof Van Ewijk, Arnauld Verschuur, Ajay Vora, Willi Woessmann, Olga Zajac-Spychala, Michel Zwaan, Maria, O, Eva, B, Pamela R, K, Olga, K, Marko, O, Reineke A, S, Gilles, V, Achini, F, Balduzzi, A, Beck Popovic, M, Beishuizen, A, Bergamaschi, L, Biondi, A, Bourdeaut, F, Braicu, E, Brok, J, Brugières, L, Burke, A, Calaminus, G, Casanova, M, Choucair, M, Cleirec, M, Corbaciouglu, S, Genoveva Correa Llano, M, De Rojas, T, Domínguez Pinilla, N, Elmaraghi, C, Ferrari, A, Fossa, A, Gaspar, N, Herold, N, Karapiperi, K, Karu, M, Kjærsgaar, M, Knörr, F, Koenig, C, Kranjcec, I, Krawczyk, M, Lehmberg, K, Lehrnbecher, T, Lunesink, M, Massano, D, Matijasic, N, Merks, H, Metzler, M, Michalski, A, Minkov, M, Morland, B, Niktoreh, N, Oltenau, E, Orbach, D, Owens, C, Papachristidou, S, Pasqualini, C, Pavlovic, M, Perez Albert, P, Poyer, F, Radulovic, I, Reinhardt, D, Rebelo, J, Roser, E, Russo, I, Scheinemann, K, Schindera, C, Schrappe, M, Sehested, A, Sehouli, J, Spreafico, F, J Strauss, S, Stutterheim, J, Svojgr, K, Tzotzola, V, Van Ewijk, R, Verschuur, A, Vora, A, Woessmann, W, Zajac-Spychala, O, and Zwaan, M

Subjects
Europe, Adolescent, Oncology, Neoplasms, Childhood cancer, essential medicines, SIOPe, Humans, Antineoplastic Agents, Child, Medical Oncology, Drugs, Essential
Abstract

Background: Shortages and unequal access to anticancer medicines for children and adolescents are a reality in Europe. The aim of the European Society for Paediatric Oncology (SIOPE) Essential Anticancer Medicines Project was to provide a list of anticancer medicines that are considered essential in the treatment of paediatric cancers to help ensure their continuous access to all children and adolescents with cancer across Europe. Methods: This pan-European project, done between Jan 20, 2020, and Feb 18, 2022, was designed to be a systematic collection and review of treatment protocols and strategies that are used to treat childhood cancer in Europe. We formed 16 working groups on the basis of paediatric cancer types, and which were based on the existing SIOPE Clinical Trial Groups. Workings groups consisted of representatives from the SIOPE Clinical Trial Groups, Young SIOPE members, and senior paediatric oncology experts. Each group collected existing treatment protocols that are used to treat the respective cancer types in Europe. Medicines from the standard group of each protocol were extracted. For medicines not on the WHO Essential Medicines List for children (EMLc) 2017, working groups did a literature search to determine whether the medicines should be defined as essential, promising, or neither essential nor promising. Each group provided an individual summary, and all medicines that were considered essential by at least one group were combined in a joint list. Findings: The working groups identified 73 treatment protocols used in Europe and defined 66 medicines as essential. For several newer medicines, such as kinase inhibitors or tisagenlecleucel, the supporting evidence was insufficient to consider them essential, so these medicines were defined as promising. 25 medicines were considered promising by at least one working group. 22 (33%) of the 66 essential and none of the promising medicines were included in the WHO EMLc 2017. The WHO EMLc 2021 included two new medicines (everolimus and vinorelbine) following applications we made as a result of this project. Interpretation: Medicines that were defined as essential within this project should be available for the treatment of childhood and adolescent cancer continuously and across Europe. This list can be used to support and guide stakeholders and policy makers in negotiations on a national and European level regarding shortages, accessibility, and affordability of these medicines. Funding: None.

Published
2022

9. Novel TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA)

Author

Aurora Feliu, Milen Minkov, Natascia Campostrini, Clara Camaschella, Fahd Al Manjomi, Laura Silvestri, Francesca Totaro, Luigia De Falco, Alessia Pagani, Carlo Dufour, Achille Iolascon, Dennis G. Van Vuurden, Domenico Girelli, Antonis Kattamis, Carmelo Piscopo, Antonella Nai, De Falco, L, Totaro, F, Nai, A, Pagani, A, Girelli, D, Silvestri, L, Piscopo, C, Campostrini, N, Dufour, C, Al Manjomi, F, Minkov, M, Van Vuurden, Dg, Feliu, A, Kattamis, A, Camaschella, C, Iolascon, Achille, Ceinge, centro di Ingegneria Genetica e Biotecnologie Avanzate, San Raffaele Scientific Institute, Department of Clinical and Experimental Medicine, University of Verona (UNIVR), Dipartimento di Ematologia e Oncologia Pediatrica, Istituto G. Gaslini, Head of Pediatric Hematology/Oncology Department, Pediatric Hematology/Oncology, Sant'Anna Children's Hospital, Department of Pediatrics, VU University Medical Center [Amsterdam], Hospital de Pediatria Combate de los Pozos, First department of Pediatrics, University of Athens School of Medicine, Dipartimento di Biochimica e Biotecnologie Mediche, Università degli Studi di Napoli, DE FALCO, L, AL MANJOMI, F, VAN VUURDEN, Dg, Camaschella, Clara, Iolascon, A., Pediatric surgery, and CCA - Innovative therapy

Subjects
Male, Silent mutation, TMPRSS6, Microcytic anemia, In silico, DNA Mutational Analysis, Mutation, Missense, medicine.disease_cause, Frameshift mutation, 03 medical and health sciences, 0302 clinical medicine, Hepcidins, Hepcidin, Genetics, medicine, Humans, Missense mutation, Child, Frameshift Mutation, Genetics (clinical), mutations, iron deficiency anemia, 030304 developmental biology, 0303 health sciences, Mutation, Anemia, Iron-Deficiency, biology, Serine Endopeptidases, Membrane Proteins, Life Sciences, medicine.disease, Molecular biology, Pedigree, Enzyme Activation, Child, Preschool, 030220 oncology & carcinogenesis, biology.protein, Female, Antimicrobial Cationic Peptides
Abstract

International audience; Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels. In this paper we describe 12 IRIDA patients belonging to 7 unrelated families and identify 10 (9 novel) TMPRSS6 mutations spread along the gene sequence: 5 missense, 1 non sense and 4 frameshift. The frameshift and non sense mutations are predict to result in truncated protein lacking the catalytic domain. The causal role of missense mutations (Y141C, I212T, R271Q, S304L and C510S) is demonstrated by in silico analysis, their absence in 100 control chromosomes and the high conservation of the involved residues. The C510S mutation in the LDLRA domain in silico model causes an intra-molecular structural imbalance that impairs matriptase-2 activation. We also assessed the in vitro effect on hepcidin promoter and the proteolytic activity of I212T and R271Q demonstrating a reduced inhibitory effect for the former mutation, but surprisingly a normal function for R271Q which appears silent in vitro. Based on mRNA expression studies I212T could also decrease the total amount of protein produced, likely interfering with mRNA stability. Collectively, our results extend the pattern of TMPRSS6 mutations associated with IRIDA and propose a model of causality for some of the novel missense mutations.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results